Archive · 6 Jan 2026
Novo Nordisk Lowers Wegovy Pill Prices for Self-Pay Patients
Novo Nordisk is making its new Wegovy weight-loss pill more affordable for people who pay for it themselves.
Starting in January 2026, the lower doses will cost $149 a month, and the higher doses will cost $299 a month.
This is to help more people get the medicine without needing insurance.
The pill is a new way to take the same medicine that was already available as an injection.
Studies show that the pill can help people lose a lot of weight if they take it correctly.
Doctors say that the best treatment is the one that people can stick to for a long time.
Novo Nordisk hopes that making the pill cheaper and easier to get will help more people use it.
Novo Nordisk will offer the oral Wegovy pill at $149/month for lower doses and $299/month for higher doses starting January 5, 2026, for self-pay patients.
The pricing strategy aims to bypass insurance hurdles and make the medication more accessible.
The FDA approved the oral version of Wegovy in late 2025, providing a needle-free alternative to the injectable form.
Clinical trials show that the 25 mg oral dose can help users lose an average of 16.6% of their body weight over 64 weeks.
Doctors emphasize that patient adherence to the treatment plan is crucial for long-term success, regardless of the format (pill or injection).
- Who
- Novo Nordisk
- What
- Lowering prices for the oral version of Wegovy
- When
- Starting January 5, 2026
- Where
- United States
- Why
- To expand access to weight-loss medication beyond insurance coverage
- Company
- Novo Nordisk
- Drug
- Wegovy (oral semaglutide)
- Price (1.5 mg/4 mg)
- $149 per month
- Price (9 mg/25 mg)
- $299 per month
- Availability
- January 5, 2026
- FDA Approval
- Late 2025
- Weight Loss (25 mg)
- 16.6% average over 64 weeks
- Placebo Weight Loss
- 2.7% average over 64 weeks
